Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Claudio I. Savulsky
A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine
British Journal of Cancer
Cancer Research
Oncology
Related publications
A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies
Cancer
Cancer Research
Oncology
Phase I Dose-Finding Study of Eribulin and Capecitabine for Metastatic Breast Cancer: JBCRG-18 Cape Study
Breast Cancer
Nuclear Medicine
Radiology
Pharmacology
Oncology
Imaging
Medicine
Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy Volunteers
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
The Insulin-Like Growth Factor-I Receptor Inhibitor Figitumumab (CP-751,871) in Combination With Docetaxel in Patients With Advanced Solid Tumours: Results of a Phase Ib Dose-Escalation, Open-Label Study
British Journal of Cancer
Cancer Research
Oncology
A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors
BMC Cancer
Cancer Research
Oncology
Genetics
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies
Clinical Cancer Research
Cancer Research
Oncology
Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
British Journal of Cancer
Cancer Research
Oncology
A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors
Oncologist
Cancer Research
Medicine
Oncology